ReSync Bio to Democratize AI-Powered Drug Discovery with NVIDIA BioNeMo
ReSync Bio, a technology company providing AI-enabled drug discovery solutions, today announced that it has integrated NVIDIA BioNeMo NIM microservices to accelerate its scalable, high throughput AI tools for drug discovery teams. Through this collaboration, ReSync offers seamless, no-code access to the suite of small molecule NVIDIA NIM microservices, empowering drug discovery teams to harness advanced AI without coding expertise.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250319575218/en/
Image of the ReSync platform showing the integrated output of a partner model from NVIDIA.
The NVIDIA BioNeMo platform provides state-of-the-art AI tools tailored for drug discovery. Its small molecule NIM microservices, such as GenMol for molecular generation and DiffDock for docking predictions, enable researchers to design, optimize, and evaluate molecules with unprecedented speed and accuracy.
The ReSync platform utilizes NVIDIA NIMs for drug discovery by managing the necessary infrastructure and user interfaces for advanced AI models. Working together with NVIDIA, ReSync has integrated NVIDIA’s core small molecule NIM microservices, DiffDock, MolMIM, and GenMol. Combined with other AI models on ReSync’s platform, including ADME and Toxicity predictions, this collaboration allows users to run a full suite of in-silico analysis throughout the Design - Make - Test - Analyze lifecycle. Teams with limited computational resources can now use ReSync to easily run large-scale virtual screening workflows to quickly explore chemical space.
ReSync’s web platform enables customers to store large volumes of virtual compounds securely, run open-source and custom AI models, and track their experimental progress through synthesis and assays. ReSync’s robust queue management and compute scalability provides customers with industry-leading capabilities for AI-enabled drug discovery, enabling a “lab in the loop” with high throughput virtual screening.
As computational demands grow, ReSync ensures that users can access the necessary resources without worrying about infrastructure management. This scalability allows organizations of any size to leverage the full potential of NVIDIA AI tools while focusing on their core research goals.
“AI has transformed digital drug discovery, but many biotechs and pharma remain limited by their ability to deploy and manage AI infrastructure,” said Mihir Trivedi, CEO of ReSync Bio. “Integrating NVIDIA BioNeMo helps bridge this gap by making advanced AI tools accessible to every drug discovery team—no coding required.”
By integrating NVIDIA’s generative AI capabilities, ReSync is poised to help biotechs accelerate drug discovery timelines and reduce development costs for small molecule therapeutics.
ReSync will be showcasing its platform, including using NVIDIA NIM microservices, at the Bio-IT World Conference & Expo from April 2-4, 2025 in Boston, MA at Booth #209.
To learn more about ReSync or request a trial, fill out our contact form here or book a demo here.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250319575218/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Unity Announces Enhanced Engine Performance and Stability, New Platforms, and AI-Powered Workflows at GDC 202519.3.2025 17:00:00 CET | Press release
Unity 6 Updates were tested with customers in production environments pre-release to better support developers across the full lifecycle of game development GDC – Unity (NYSE: U), the leading platform to create and grow games and interactive experiences, today announced that developers can expect enhanced performance and stability, expanded platform support, and new AI-powered workflows in the three Unity 6 Updates planned for 2025, with the first, Unity 6.1, landing in April. “We don’t want developers to have to choose between stability and new features, or between fidelity and ubiquity. We are committed to delivering it all," said Matt Bromberg, CEO and President of Unity. “Pressure testing new releases in production environments with our partners is enabling much higher quality builds.” Unity 6.1 will enable higher frame rates, smoother gameplay, lower CPU/GPU load for better device performance, and improved debugging for easier optimization. Additionally, Unity is doubling down on
Venture Global Receives Non-FTA Export Authorization for CP2 LNG19.3.2025 15:55:00 CET | Press release
U.S. Department of Energy grants CP2 LNG approval to export to non-FTA countries Today, Venture Global received approval from the U.S. Department of Energy to export liquefied natural gas (LNG) to non-FTA countries for its third project, CP2 LNG, located in Cameron Parish, Louisiana. Venture Global CEO Mike Sabel issued the following statement: “CP2 LNG is a vital project for the U.S. economy, balance of trade, and global energy security. We are grateful for the Trump Administration’s return to regular order and regulatory certainty that will allow us to further expand U.S. LNG exports, which have consistently been found to be in the public interest across multiple Administrations. This will enable us to provide our allies around the world with American LNG in just a few years and for decades to come.” Earlier this month, Venture Global announced that it has launched the FID process for CP2 LNG. To date, the initial phase of CP2 LNG has been sold through 20-year sales and purchase agre
Bregal Milestone Announces Strategic Growth Investment in Ridango19.3.2025 15:41:00 CET | Press release
Bregal Milestone, a leading European software growth private equity firm, today announced a majority strategic growth investment in Ridango, a global provider of mission-critical public transportation software. The investment is made in partnership with founder Erki Lipre and the Ridango management team. Terms of the transaction were not disclosed. Founded in 2009, Ridango is a global market leader in intelligent transportation software for public transport authorities, municipalities, cities, and private transport operators. Ridango has built one of the world’s leading integrated automated fare collection and operations control software platforms, serving more than 150 customers in over 25 countries across five continents. The Company’s modern software provides end-to-end transit management services, from account-based ticketing to contactless bank card acceptance, real-time passenger information, and automatic vehicle location operations management to deliver better transit services,
Stackline and Redslim Partner to Deliver Unparalleled Retail Intelligence and Data Integration for Global Brands19.3.2025 14:00:00 CET | Press release
Stackline, the leader in retail intelligence and data-driven commerce solutions, has announced a strategic partnership with Redslim, a leading data management company specializing in optimizing syndicated market data. This collaboration provides global CPG and CHC brands with a high-fidelity, 360-degree view of category performance—equipping them to make smarter, faster decisions in an increasingly competitive marketplace. Stackline’s industry-leading solutions provide brands and manufacturers with deep, data-driven insights into category performance. By tracking sales volume, traffic, and conversion rates across the world’s top retail ecosystems, including Amazon, Stackline enables brands to decode the omnichannel shopper journey with precision. Its digital shelf solution delivers advanced analytics to optimize product listings, enhance digital shelf performance, and drive sustained ecommerce growth. Redslim specializes in transforming fragmented market measurement data into harmonize
Fujirebio Enhances Supply Chain Operations with Kinaxis19.3.2025 12:00:00 CET | Press release
Japanese biotech leader adopts orchestration to more rapidly respond to demand fluctuations Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced that Fujirebio Inc., a Japanese multinational biotechnology company, is using Kinaxis and its AI-powered supply chain orchestration platform Maestro™ to enhance and optimize its supply chain operations. Fujirebio Inc., a consolidated subsidiary of Fujirebio Holdings Inc., is a global leader in the development, manufacturing and sales of clinical diagnostic reagents and testing equipment. Fujirebio is currently focused on strengthening and expanding its Contract Development and Manufacturing Organization (CDMO) by leveraging high-quality raw materials in the immunology field and advanced reagent development technologies. To accelerate the company’s growth, Fujirebio needed to strategically link and synchronize its entire supply chain process, which spans raw material production to final product shipment
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom